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Abstract: We present g-Nomic, a pharmacogenetics interpretation software that analyzes
globally a prescribed medication taking into account the personal background genetics, drug–
drug interactions, lifestyle, nutritional supplements, inhibitors, inducers, and other risks to
analyze primary or secondary metabolism pathways. G-Nomic provides a set of recommen-
dations describing the suitability of a given combination of drugs for each patient according
to their genes and polymedication. G-Nomic is updated monthly including data from the new
drugs to be included, their known interactions, and the relevant pharmacokinetic biomarkers.
For the interactions, the list is curated manually, only keeping those with clinical relevance.
For each drug, their FDA and EMA drug labels are accessed, to check for relevant enzymes
and transport proteins that influence its pharmacokinetics, and for their ability to induce or
inhibit other enzymes, particularly the CYP-450 system. When this information is not
available, a PubMed search is made to look for these characteristics. In addition, a distinction
is made between drugs and prodrugs. A query on the g-Nomic software begins with entering
the medication by either their common or commercial name. Non-pharmacological sub-
stances can be also added or selected under “lifestyle habits”. The lifestyle list is dynamic,
showing only the substances known to interact with the drugs that are currently selected, and
includes herb compounds, such as St. John’s wort, as well as proper lifestyle substances such
as grapefruit or cigarette smoking. The software provides a list of the genes classified as
primary biomarkers as candidates for genetic testing, and a list of the interactions that have
been detected. If genetic information is available then, or is made available at a later point,
these results can also be entered and the software returns pharmacogenetics recommenda-
tions regarding specific genotypes. g-Nomic takes all the above-mentioned parameters in an
easy and user-friendly tool making prescription safer.
Keywords: pharmacogenetics, SNP, drug-drug interaction, drug-lifestyle, drug-herb,
software
Introduction
Adverse drug reactions (ADRs) are one of the leading causes of death in developed
countries. In the United States of America, it is reported that more than 100.000
people died each year in the USA only, due to ADR even if they take medicines
correctly prescribed according to the protocol.1 In Spain, more than 5% of ADR-
related hospitalizations had a fatal outcome.2 According to statistics, senior
Americans take, on average, more than five drugs.3 and 40% of the ADR could
be avoided.4 if pharmacogenetics criteria were taken into account.
Nevertheless, many practitioners confirm that the problem with medication
persists even after doing a pharmacogenetics test such as Roche’s Amplichip.5 the
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first FDA-approved pharmacogenetics test, designed to
detect variants in genes involved in drug metabolism.
The main reason for this issue is that pharmacogenetics
tests alone are significant only in the case of monotherapy,
but in combination therapy – most of the cases – the final
effect of the drug must be assessed by taking into account
the interactions with the other medications taken by the
patient as well as the lifestyle. Consequently, approxi-
mately 30% of the variability in response to prescriptions
is due to genetics, but 60% of the problems are due to
drug–drug interactions, drug–lifestyle interactions, and
inhibitions and inductions produced by polymedication.
The remaining 10% corresponds to problems linked to
age, absorption, and drug side effects among others.
Pharmacogenetics studies the actions of the pharmaco-
logical response to drugs depending on the genetic back-
ground of a patient. Single nucleotide polymorphisms
(SNPs) are at the basis of human variability originating
the classical drug-metabolizing categories of normal or
extensive metabolizers, intermediate, poor and rapid or
ultra-rapid metabolizers. The changes produced by these
non-pathological mutations may be silent and they only
will be manifested when a drug for its therapeutic action,
depends on the normal functioning of the enzymes, trans-
porters or therapeutic targets emitted by these genes with
these SNPs.
This can affect receptors like VKORC1, transporters
like the ABC and SLC families, or enzymes involved in
the metabolism of drugs belonging to Phase I such as the
P450 family or Phase II like UGT, NAT, and GST.
Therefore, the correct application of pharmacogenetics
reduces the costs of medical assistance, minimizes adverse
reactions to medications, avoids therapeutic failures, and
allows prescribing in a safe and more efficient way.
There are already organizations and consortiums world-
wide with the aim of achieving safe and effective pharmaco-
logical treatments: PGRN (Pharmacogenomics research
network), PharmGKB, CPIC, and Dutch International
Working Group among others.6–8 Drug agencies worldwide
already recognize SNPs involved in the metabolism and
transport of certain drugs. In addition, new drug labels
already include pharmacogenetics markers and drug–drug
or drug–lifestyle interactions based on pharmacogenetics
markers. This has contributed significantly to make pharma-
cogenetics a viable milestone by listing the genetic markers
that are relevant and their clinical significance.
However, as stated above, aside from the data gathered
from pharmacogenetics studies, there is an important issue
of exploring and taking into account the effects of drug–
drug interactions. While the presence of a loss-of-function
variation in the gene encoding for an enzyme will abolish
its activity, it is known that substances with inhibitory
capacity can also impair the enzymatic activity even in
the absence of loss-of-function variants. Therefore, a per-
son who would be categorized as a normal metabolizer
based solely on a genetic test would experience phenocon-
version to a poor metabolizer when exposed to a strong
inhibitor.
Likewise, enzyme inducers can increase enzymatic
activity over what a genetic test might indicate.9 This
rationale can be extended to drug–herb and drug–lifestyle
interactions as potential modulators of drug metabolism
and therefore of drug response. Taken the above in con-
sideration, it is hard to achieve personalized prescription
without considering the medication of the patient as a
whole including lifestyle, food, nutritional supplements,
tobacco, abuse drugs, and herbal plants.
Therefore, with the aim of making prescription more
secure to both, doctor and patient, we have developed g-
Nomic, a novel pharmacogenetics interpretation software.
The g-Nomic pharmacogenetics interpretation software
can be accessed via de website https://www.eugenomic.com/
en/home.html. Once connected to this website, there is head-
ing in the main menu ≪g-Nomic Pharmacogenetics≫. The
user can have a free trial version for 14 days with limited
access and functionality. For the full version, a nominal fee
per year is required.
Methods
The pharmacogenetics interpretation software, g-Nomic, is
an initiative in the area of biotechnology, that already
integrates information of more than 2,000 active ingredi-
ents (equivalent to more than 10,000 drug brand names)
with genetic data in order to grant practitioners safety in
the medical prescription.
Active ingredients
We have defined as active ingredient either medicine,
food, food supplement, vitamins, natural herbs, or abuse
drug. In g-Nomic, there is information related to more than
2,000 active ingredients. Of these 1,206 active ingredients
do not have any pharmacogenetics information and 934
have pharmacogenetics information either as a substrate,
inducer, or inhibitor.
The active ingredients present in g-Nomic without
pharmacogenetics information are relevant as the software
Sabater et al Dovepress
submit your manuscript | www.dovepress.com
DovePress









































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
gives evidence regarding relevant drug–drug interactions,
drug with lifestyle, inhibitors, inducers, risks associated
with medication as well as genes related to the medication.
All data entered are for in vivo. No data are entered to
g-Nomic if is in vitro or in animals.
Input
g-Nomic pharmacogenetics interpretation software inputs
for each medication possible substrates (drug or prodrug),
primary and secondary pathways, inhibitions (competitive
or allosteric, normal or strong) and inductions (normal or
strong), the interaction of these drugs with other drugs,
interactions with lifestyle, the possible risks associated
with medication and alerts about published guidelines
regarding medication, and finally the genetic information
in terms of SNPs (if known) of the individual to be
categorized as EM, IM, UM, or PM (Figure 1).
Development
The development of g-Nomic took place in two phases.
Phase I had the objective of compiling the initial informa-
tion of the database, that is the drugs to be included, their
known interactions, and the relevant pharmacokinetic bio-
markers. Once the database was populated, and the soft-
ware released, Phase II deals with updating it regularly
with new information.
For the interactions database, a preliminary list was
elaborated by reviewing focused literature.10,11 This list
was curated manually, only keeping the relevant interac-
tions to avoid the phenomenon known as “alert fatigue”,12
observed when there is an overload of drug interaction
alerts with limited relevance that leads professionals to
ignore notifications. Relevant interactions were defined as
those that warrant taking some sort of measure, from
monitorization to a strict contraindication of concurrent
use, which roughly matches categories 1–3 of the
Hansten and Horn significance scale.
Data on metabolic pathways were compiled by select-
ing all the drugs present in the Spanish vademecum as a
starting point later it has been updated will all new
released drugs and updated with the FDA and EMA infor-
mation. For each drug, we accessed their FDA and EMA
drug labels, when available, to check for relevant enzymes
and transport proteins and for their ability to induce or
inhibit other enzymes, particularly the CYP-450 system.
When this information was not available, a PubMed search
was made to look for these characteristics. In addition, a
distinction was made between drugs and prodrugs (ie,
whether the parent drug is active, or it requires an activat-
ing transformation first).
Prodrugs that in vivo are transformed into active drugs
without enzymes that can have altered activity due to
SNPs in their codifying genes, are considered as drugs
Patient reality when taking a drug
Mainly in the liver
Personal
On enzyme level
























Figure 1 Patient reality when taking a drug. It is shown the different elements analyzed and taken into account by the interpretation software g-Nomic: Primary (PP) or
secondary (SP) pathways, personal background genetics – Extensive (EM), Intermediate (IM), Ultra (UM), and Poor (PM) Metabolizers, drug–drug interactions, lifestyle,
nutritional supplements inhibitors and inducers, and other risks.
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and not as prodrugs. Therefore, only substances that are
activated by enzymatic reactions are considered prodrugs
in our database.
After the initial population of the database, the infor-
mation is kept up-to-date by a monthly review of reported
changes in drug labels, both from FDA and EMA, as well
as automated PubMed searches, and constant implementa-
tion of the results once they are reviewed. In-depth review
of bibliography, targeted to particular drugs of interest, can
also be performed outside this schedule. Only data from
human studies (both patients and healthy subjects) are
eligible to be included in the software. Results from in
vitro studies, as well as experimentation in animals, are
considered too preliminary to be included.
g-Nomic takes all the above-mentioned parameters in an
easy and user-friendly tool making prescription safer. The
first release was available in 2014. Since then more than
3,000 users have accessed this tool. Currently, it holds at
least 8,000 drug–drug interactions from clinical publica-
tions, 1,900 drug–lifestyle interactions, 1,500 risks asso-
ciated with medication, and 600 polymorphisms in 50
genes. What makes g-Nomic pharmacogenetics interpreta-
tion software so powerful is the interacting algorithm that is
capable of mixing all the inputs in just a few seconds giving
presently more than 2,300,000 possible combinations.
Algorithm
gNomic is a Web-based Application developed in Java. For
each gene, information is provided in terms of which drugs
are substrate, inhibitor, and inducers. For each gene, there is
also definition of the genotypes, phenotypes and poly-
morphisms that define the activity. Each gene also has in
the definition if it belongs to Phase I, Phase II, or if is a
transport protein and the type, as well as other type of
activity. As this will be defining a set of rules in the
algorithm, there is a specific way of determining the excep-
tions to the so-called standard messages, following the
directions of the guidelines provided by medicine agencies.
Workflow
A query on the gNomic software begins with entering the
medication. Each drug can be entered by either their common
name (eg, topiramate) or a commercial name (eg, Topamax).
It contains the commercial names of the Spanish
Vademecum and many of the USA and some of France
so, outside of Spain, it is recommendable to enter the
drugs by their generic or technique name and not by the
commercial name.
Non-pharmacological substances can be selected in a
“lifestyle habits” tab. The lifestyle list is dynamic, show-
ing only the substances known to interact with the drugs
that are currently selected, and includes herb compounds,
such as St. John’s wort, as well as proper lifestyle sub-
stances such as grapefruit or cigarette smoking. These
substances can influence the outcome of a therapy, yet
they are likely to be overlooked as they are not part of
the actual pharmacologic therapy. In 2018, there are a total
of 250 herbs in the software.
The software provides a list of the genes classified as
primary biomarkers as candidates for genetic testing, as
well as a list of the interactions (drug–drug and drug–
lifestyle) that have been detected. If genetic information
is available then or is made available at a later point, these
results can also be entered and the software may return
pharmacogenetics recommendations regarding specific
genotypes. Effects on lower relevance biomarkers, or sec-
ondary pathways, are hidden by default but can be toggled
on by the user. The report messages are generated on the
fly; the user can navigate back and forth between the
different tabs, changing medication or adding genetic
results, and the messages will update in real time without
the need to start over.
The interactions can come from clinical reports, but can
also be a consequence of the known pharmacokinetic prop-
erties of the drugs. Specifically, a substance can be a known
inhibitor or inducer of an enzyme that is a primary biomar-
ker of a drug. These kinds of interactions are usually men-
tioned in drug labels, but normally the precipitating
substances are not referred by name but by their effect on
pharmacokinetic pathways (eg, avoid CYP3A4 inhibitors).
The software works on a semiquantitative model for these
kinds of interactions, so the presence of a single substance
whose inhibitory potency has been labeled as “strong”
would trigger an alert, whereas for weaker strength cate-
gories, an increasing number of co-administered inhibitors
are required to reach the alert threshold. The notifications
are as concise as possible, as we have tried to convey the
most crucial information in short messages that can be read
and understood quickly. This is because we have conceived
the software to be used effectively in a doctor’s office,
where time is usually limited.
Disclaimer
The g-Nomic pharmacogenetics interpretation software is
a useful tool to be used on the point of care with the sole
aim to help the practitioner to take a decision regarding
Sabater et al Dovepress
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patient’s medication. The last word is for the doctor as the
only one who has the complete medical history together
with the physical exploration and other relevant data that
cannot be interpreted at this time by a machine.
Results
Below it will be described different outputs of the results
that can be obtained by the use of g-Nomic interpretation
software applied to daily basis medication examples taking
into account drug–drug interaction, drug–lifestyle, inhibi-
tions, inductions, pharmacogenetics, and risks associated
with medication:
Input data to g-Nomic
Patient’s data can be entered to g-Nomic software using
three alternative ways:
(a) Manual entry
The user enters manually patient’s data. In this case, name
and surname or reference number and date of birth are
required. After this can be entered for the patient as well as
studied genes.
(b) Using Import button
This is functionality is currently only available for internal
use. It allows to import pharmacogenetics data from an
excel file containing data from several patients, with the
following format: patient name, surname, clinic, reference
number, gene, and genotype.
(c) Using Import button PGxAlgorithm
This is functionality is currently only available for internal
use. It allows to import pharmacogenetics data from an excel
file with the following information: rsnumber, gene, position,
genotype via upload of this file the system generates a patient
record with all the genes found in the file and the correspond-
ing predictive phenotype. A file with 925,000 records takes
less than 2 mins to upload and generates the predictive
phenotypes for the known genes in g-Nomic.
Case of a drug and a patient with PM
phenotype
Aripiprazole is a drug used for schizophrenia metabo-
lized primarily by CYP2D6 and CYP3A4. According to
the dosage and administration given in the Drug label
from FDA,13 it is recommended administering half of
the usual dose in case of CYP2D6 PM patients. When
checking g-Nomic pharmacogenetics interpretation soft-
ware for this eventuality, the relevant information
obtained is shown in Figure 2
Case of a prodrug
Case of a patient taking Tamoxifen (used for the treat-
ment of breast cancer type ER+). Tamoxifen is consid-
ered a prodrug and is converted to its active drug
endoxifen via the CYP2D6 and CYP3A4 genes. If the
patient is poor metabolizer for CYP2D6 (*5*5 for exam-
ple), this activation will happen very slowly and there
will be a much lower dose of the active ingredient,
endoxifen, thus leading to an inefficient treatment. This
information can be obtained in the report obtained by
using g-Nomic (Figure 3)
Case of drug interactions
This occurrence is represented by a medication combining
Ticagrelor + Simvastatin. Ticagrelor, with the brand name
of Brilinta, it is used as a platelet inhibitory drug, and in
common with simvastatin, is metabolized by CYP3A4.
Therefore, when the two drugs are administered together,
there is a decrease in the metabolism of simvastatin redu-
cing its clearance.14 The AUC of simvastatin is expected
an increase to two to threefold, increasing the risk of
muscle damage.15 In Figure 4, it can be observed the
information given by g-Nomic when consulting about
this drug combination.
Case of a drug in combination with
lifestyle
Tamoxifen + calcium
Calcium increases the side effects of hypercalcemia pro-
duced by tamoxifen. Therefore, in the case of breast can-
cer patients treated with tamoxifen, it is advisable not to
give calcium, as a lifestyle supplement+, in combination
with tamoxifen because life-threatening metabolic compli-
cation of flare hypercalcemia develops (Figure 5). In the
case of hypercalcemia, gallium nitrate allows restarting
tamoxifen safely.16
Case of a prodrug inhibition
As a representative of this situation, we can take as an
example the case of tamoxifen when taken together with
Dovepress Sabater et al
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paroxetine (Figure 6). As stated in the FDA drug label of
paroxetine: Tamoxifen is a prodrug requiring metabolic
activation by CYP2D6.17 Inhibition of CYP2D6 by
paroxetine may lead to reduced plasma concentrations of
an active metabolite (endoxifen) and hence reduced the
efficacy of tamoxifen.
Figure 2 g-Nomic pharmacogenetics report for aripiprazole of a patient showing a PM CYP2D6 phenotype.
Figure 3 g-Nomic pharmacogenetics report for a CYP2D6 PM individual prescribed with tamoxifen.
Figure 4 Drug interaction between simvastatin and ticagrelor: The two drugs are metabolized by CYP3A4.
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Case of an inducer drug
This case can be illustrated through the example of the
pharmacological response produced by the combination of
Paroxetine + Rifampicin. Basically, Rifampicin, also
known as rifampin, is an antibiotic used to treat several
types of bacterial infections. However, this drug is a potent
inducer of certain cytochrome P-450 enzymes including
CYP2D6,18 which will accelerate the metabolism of par-
oxetine, and in consequence, it could lead to therapeutic
failure (Figure 7). To prevent this effect, drugs metabo-
lized by P-450 enzymes may require adjustments when
rifampin is administered concomitantly.
Case of risks associated with medication
There can be many risks associated with medication which
are illustrated here by the case of administrating drugs such
as:Metformin for treating type 2 diabetes, Quetiapine to treat
schizophrenia, Fluticasone used to relieve allergic and non-
allergic nasal symptoms, Salmeterol as a Bronchodilator
Agent, Valsartan widely used to treat high blood pressure
or Haloperidol as an antipsychotic. In the case of
Haloperidol, Quetiapine and Salmeterol: These drugs may
prolong the QT interval and/or induce Torsades de Pointes
(Figure 8). If one of the prescribed drugs is an antiarrhyth-
mic, it might be problematic to discern whether the indivi-
dual developed the arrhythmia due to his heart condition or
due to the medication.
Discussion
The vast information available nowadays regarding phar-
macogenetics needs to be implemented in the clinical prac-
tice to accomplish the objective of providing a personalized
Figure 5 Interpretion of g-Nomic in the case of drug–lifestyle interaction: Tamoxifen plus calcium.
Figure 6 g-Nomic report in the case of the prodrug inhibition caused by paroxetine on the formation of endoxifen from tamoxifen.
Dovepress Sabater et al
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therapy which is efficient and secure.19 In this respect,
several organizations and consortiums have been created
worldwide with the aim of achieving safe and effective
pharmacological treatments: PGRN, PharmGKB, CPIC,
and D.I.W.G among others. Accordingly, and with the aim
of making prescription more secure to both, doctor and
patient, we have developed a pharmacogenetics software,
g-Nomic, which is described and presented in this article.
Performing a drug prescription at first attempt is a complex
situation and both, practitioners and pharmacists take a lot of
responsibility especially considering the very short time due to
lack of time in medical consultations. In this regard, knowing
Figure 7 g-Nomic report in case of the drug induction of several cytochrome P-450 enzymes produced by Rifampin which may low plasma levels of drugs such as Paroxetine.
Active ingredient
Haloperidol
This drug may cause neutropenia or agranulocytosis.
This drug may cause thrombopenia.
This drug may cause liver damage (cholestatic jaundice)
This drug may be contraindicated for elderly people (see “other information of interest”)
This drug may prolong the QT interval and/or induce torsades da pointes.
This drug can induce gynecomastia.
This drug is a DAO inhibitor and can induce migraine.
This drug may cause neutropenia or agranulocytosis.
This drug may prolong the QT interval and/or induce torsades de pointes.
This drug can induce gynecomastia.
This drug may be contraindicated for elderly  people (see “other information of interest”)
This drug may prolong the QT interval and/or induce torsades de pointes.
This drug is contraindicated during pregnancy (category D)
This drug can cause acute kidney injury






Figure 8 g-Nomic report showing risks associated with specific medications.
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the genetic polymorphisms of a patient helps to adjust the dose
for the intended pharmacological effect and whether it would
be needed to seek a therapeutic alternative. In general, patients
are polymedicated and the effect of various drugs administered
together may be different (produce ineffectiveness or toxicity)
compared to when they are administered alone. Frequently,
even if a person could take specific drugs individually accord-
ing to their genetic background, the combination of drugs
themselves could inhibit or induce the other producing a drug
adverse reaction. Almost, all drug treatments have the risk of
not being suitable for that particular person, and traditional
medicine practice uses the try-and-see method until the patient
has a successful treatment. Unfortunately, the try-and-see
method sometimes does not work because the patient already
had a fatal effect. In g-Nomic, we have added customized lists
of possible interacting lifestyle per each drug so that physician
should only click to those confirmed by the patient.
To successfully apply pharmacogenetics and make a pre-
scription safely and accurately, many parameters should be
taken into consideration, such as drug–drug interactions,
drug–lifestyle, inhibitions and inductions, and dose variation
according to patient studied genes. All this information can
only be interpreted together, using a pharmacogenetics inter-
pretation software like g-Nomic.
There are other pharmacogenomic software tools such as
PharmCAT, that extracts all CPIC guideline gene variants from
a genetic database, interpret the variant alleles, and generates a
report,20 GDA Pharmacogenetics, which allows integrative
study of drug response data, mutations, and gene expression
profiles focusing on a panel of more than 70 cancer cell lines
treatedwith 50,800 compounds,21 orVirtual Pharmacist, a web
tool that interpret personal genome for the impact of genetic
variation on drug response.22 However, even if these are very
valuable tools, they basically focus of genetic variation or are
very specific oriented, whereas gNomic pharmacogenetic
interpretation crosses information concerning prescribed
drugs, patient’s genetic variations to give a personalized report
with all necessary information: drug interactions, drug with
lifestyle, inhibitions, inductions, and dose variation according
to the patient’s genes. G-Nomic is designed as a practical tool
to be used in clinical practice.
Cardiology is one of the specialties where pharmacoge-
netics has a more direct impact. Taking anticoagulants as an
example, a patient starting on warfarin (acenocoumarol), can
have fatal side effects when prescribed on a standard initial
dose. On the other hand, the new oral anticoagulants, said to be
safer and more reliable than warfarin, do not have a lab test to
measure if the patient has correct drug levels, and certain
patients could have an impaired extrusion protein function
(P-gp, coded by the gene ABC1B1) that in long term could
lead to internal bleeding. In both cases, the usage of pharma-
cogenetics could have prevented these adverse events. When
prescribing a patient with an antiplatelet drug, such as clopido-
grel, because of insufficient clopidogrel-induced platelet inhi-
bition, since clopidogrel requires hepatic bioactivation via
several cytochromes, the patient could be at risk. This effect
could also be produced by polymedication. Thus, prediction is
essential to prescribe safer and avoid predictable side effects.
Furthermore, in the case of hypertension, the number of drugs
that could be prescribed is large. In this particular therapy, it is
crucial to knowhow if poly-pharmacywill inhibit or induce the
medication, leading to inefficiency or toxicity risk.
Applied pharmacogenetics can indeed avoid many emer-
gency cases, save lives and money. But to correctly apply
pharmacogenetics, interpretation software is needed since
there are too many variables to consider, including the infor-
mation provided in modern drug labels regarding possible
inhibitors or inducers.
The future of medical practice cannot be envisioned with-
out taking into account pharmacogenetics. However, in reality,
it is also very difficult to imagine all medical doctors applying
pharmacogenetics. In addition, patient can buy drugs over the
counter or take food and medical plants that could cause an
adverse reaction. Therefore, the puzzle gets complex when it
comes tomaking a full interpretation. Pharmacogenetics is still
very new, and it will take time to be fully implemented. A
possible near future would be to create a new service of “drug
surveillance” to be offered in hospitals. Trained pharmacists,
pharmacologist, or physicians, who will act as an interface
between the patient and all his general practitioners and spe-
cialists, will lead this new service. Doctors would suggest their
patients who experienced an ADR visiting the “drug surveil-
lance unit”. At this new “drug surveillance” service, medica-
tion will be checked from a personalized point of view, and
they will have the capacity to consult with different doctors to
seek the best suitable treatment. At this point, the aid of a
pharmacogenetics interpretation software like g-Nomic
would be of great help. More in the long term, we cannot
forget that we are in the digital century and for sure in years
to come artificial intelligence will be resolving most of all
problems related to drug adverse reactions. However, until
then, actions should be taken to prevent patients from experi-
encing side effects with their prescribed medication.
It is entirely in the hands of hospitals, elderly houses, and
medical practitioners on how they would like to treat their
patients: like in the last century using the try-and-see method
Dovepress Sabater et al
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or with the aid of pharmacogenetics and a pharmacogenetics
interpretation softwares like g-Nomic. The software presented
in this article addresses this issue directly by integrating infor-
mation from different sources and providing the correspond-
ing alerts in a process that is quick, simple, and concise.
Conclusions
Pharmacogenetics is still a young science, but it should be
applied in benefit of both doctors and patients. Although
important organizations perform research and publish recom-
mendations in the pharmacogenetics field, this guidance has
later no impact, because prescribers state that there are not
protocols or that it is still too early tomake any decisions in this
direction. In addition, it is clear that many factors occur in
combination when drugs are prescribed. In this regard, a tool
like g-Nomic could be a software providing a necessary aid.
Nevertheless, it has to be taken into consideration that g-Nomic
cannot replace medical doctors, as they are the only ones
handling all the medical and clinical data from the patient.
Disclosure
The name given to the pharmacogenetics interpretation
software, g-Nomic, has been registered and has a copy-
right registered in the EUIPO with file number 012876868.
Since g-Nomic is a software, it cannot be patented, but the
screens do have safe stamp copyright licensed under the
company brand of EUGENOMIC®. Marc Cendros, Juan
Sabater-Tobella and Ana Sabater work for the company
EUGENOMIC, but g-Nomic pharmacogenetics software
has been built according to guidelines and publications
without any possible conflict of interest. The authors
report no other conflicts of interest in this work.
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